Epidemiologie, Risikofaktoren und Risikostratifizierung venöser Thromboembolien (VTE) in Schwangerschaft und Wochenbett

Zusammenfassung

Venöse Thromboembolien (VTE) gehören zu den häufigsten Ursachen direkter Müttersterbefälle in den Industrieländern. Ihre Inzidenz hat in den letzten 20 Jahren signifikant zugenommen. Das absolute Risiko für VTE liegt in der Schwangerschaft zwischen 0,6–2,2/1000 Geburten, im Vergleich zu Nichtschwangeren ist das tägliche Risiko für VTE in der Schwangerschaft um das 7- bis 10-fache höher und im Wochenbett um das 15- bis 35-fache. Die Inzidenz an Lungenembolien (LE) ist während der ersten 6 Wochen nach der Geburt um das 15-fache höher als in der Schwangerschaft und bleibt bis zu 12 Wochen postpartum noch signifikant erhöht. Die fallbezogene Sterblichkeit der LE liegt zwischen 2,2–6,6%.

Grundlage der medikamentösen VTE-Prophylaxe ist eine sorgfältige Erfassung individueller Risikofaktoren und eine adäquate Risikostratifizierung. Zu unterscheiden sind präexistente mütterliche von transienten Schwangerschafts-spezifischen Risikofaktoren. Das höchste Risiko für VTE weisen Frauen mit vorangegangener VTE oder mit angeborenen Hochrisiko-Thrombophilien oder mit Antiphospholipid-Syndrom auf. Weitere bedeutende Schwangerschafts-spezifische Risikofaktoren antenatal sind das schwere ovarielle Hyperstimulationssyndrom, die Hyperemesis, größere Operationen, schwere Komorbidität (z. B. systemischer Lupus erythematodes), Hospitalisierung bei Frauen mit einem Body-Maß-Index>25 kg/m² und entzündliche Darmerkrankungen.

Herzerkrankungen, Totgeburt, systemische Infektionen, schwere postpartale Blutung in Kombination mit der Substitution von Erythrozytenkonzentraten/Gerinnungsfaktoren und/oder Operationen sowie die sekundäre Sectio sind die stärksten Risikofaktoren im Wochenbett.

Empfehlungen zu Risikostratifizierungen sind in aktuellen internationalen Leitlinien unterschiedlich. Nach der Leitlinie der Kanadischen Gesellschaft für Geburtshilfe und Gynäkologie 2014 (SOGC) wird eine medikamentöse VTE-Prophylaxe dann empfohlen, wenn das VTE-Risiko eines einzelnen oder mehrerer Risikofaktoren>1% beträgt. Die ACCP (American College of Chest Physicians)-Leitlinie 2012 bezieht sich ausschließlich auf eine Risiko-basierte VTE-Prophylaxe nach Sectio caesarea. Die jüngste RCOG (Royal College of Obstetricians and Gynaecologists)-Leitlinie No. 37a 2015 empfiehlt die Risikostratifizierung für VTE auf der Grundlage eines speziellen „risk scoring“-Systems und gewichtet die individuellen Risikofaktoren zwischen einem Punkt (niedriges Risiko) bis maximal 4 Punkte (sehr hohes Risiko).

Jede geburtshilfliche Klinik sollte über eine Checkliste wichtiger Risikofaktoren und über einen auf aktuellen Leitlinien basierenden Handlungsplan zur medikamentösen Thrombose-Prophylaxe verfügen.

Abstract

Venous thromboembolism (VTE) remains a leading cause of direct maternal deaths in the developed countries. The incidence of VTE has increased significantly during the past two decades. The absolute risk of VTE is estimated 0.6–2.2 per 1000 deliveries. Compared with age-matched non-pregnant women, the daily risk of VTE is increased 7- to 10-fold for antepartum VTE, but it is 15- to 35-fold for postpartum VTE. The incidence of pulmonary embolism (PE) during the first 6 weeks postpartum is nearly 15-fold higher compared to the incidence in pregnancy, and remains significantly increased up to 12 weeks postpartum. The case fatality rate of PE ranges from 2.2 to 6.6%.

The basis of VTE prevention is careful assessment of individual risk factors of VTE and proper risk stratification.

It is necessary to differentiate preexisting maternal from transient pregnancy-specific risk factors. Women with previous VTE or hereditary high-risk thrombophilias or with the antiphospholipid syndrome have the highest risk for VTE in pregnancy and the puerperium.Other most important pregnancy-specific risk factors in the antenatal period are severe ovarian hyperstimulation syndrome, hyperemesis, major surgery, severe comorbidities (e.g., systemic lupus erythematodes), hospitalization in women with a body mass index > 25 kg/m², and inflammatory bowel diseases.

Heart diseases, stillbirth, systemic infections, severe postpartum hemorrhage in combination with blood product replacement and/or surgery and emergency caesarean section are predominant risk factors in the postpartum period.

Recommendations for risk stratification vary among current international guidelines. According to the SOGC (Society of Obstetricians and Gynaecologists of Canada) 2014, pharmacologic VTE prophylaxis is recommended if the estimated absolute risk of one or multiple risk factors is greater than 1%.

The ACCP (American College of Chest Physicians) Guideline 2012 presents specific recommendations only for post-caesarean risk-factor-based prophylaxis.

The recent RCOG (Royal College of Obstetricians and Gynaecologists) Guideline No. 37a 2015 recommends risk stratification for VTE prophylaxis on the basis of a special risk scoring system weighting individual risk factors between one point (low risk) to a maximum of 4 points (very high risk).

A check list of important risk factors and a management plan for thromboprophylaxis based on current guidelines should be readily available in each obstetric unit.

Schlüsselwörter

venöse Thromboembolien - Schwangerschaft und Wochenbett - Epidemiologie - Risikofaktoren - Risikostratifizierung

Key words

venous thromboembolism - pregnancy and puerperium - epidemiology - risk factors - risk stratification

• Literatur

• 1 Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis 2016; 41: 3-14
• 2 Friedman AM, Ananth CV. Obstetrical venous thromboembolism: Epidemiology and strategies for prophylaxis. Semin Perinatol 2016; 40: 81-86
• 3 Rath W. Venöse Thromboembolien in Schwangerschaft und Wochenbett. In: Handbuch Gynäkologie/Geburtshilfe 2016/2017. Dimpfl Th, Fischer Th, Hasenberg A, Jackisch Ch., (Hrsg.). med public; 2016 ISBN: 978-3-86302-365-2
• 4 Blanco-Molina A, Rota LL, Di Miccio P. et al. Venous thromboembolism during pregnancy, postpartum or during contraceptive use. Thromb Haemost 2010; 103: 11
• 5 James AH, Jamison MG, Brancazio LR. et al. Venous thromboembolism during pregnancy and the postpartum period: Incidence, risk factors, and mortality. AJOG 2006; 194: 1311-1315
• 6 Say L, Chou D, Gemmill A. et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health 2014; 2: e329-e338
• 7 Knight M, Kenyon S, Brocklehurst P et al.on behalf of MBRRACE-UK Saving Lives ‘Improving Mother’s’ Care. Lessons learned to inform future maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2009-2012 Oxford National Published Epidemiology Unit, University of Oxford. 2014; ISBN 978-0-9931 267-1-0
• 8 Cantwell R, Clutton-Brock T, Cooper G. et al. Saving mother’s lives: reviewing maternal deaths to make motherhood safer: 2006-2008. The eighth report of the confidential enquiries into maternal deaths in the United Kingdom. BJOG 2011; 118 (Suppl. 01) 1-203
• 9 Knight M on behalf of UKOSS. Antenatal pulmonary embolism: risk factors, management and outcomes. BJOG 2008; 115: 453–461
• 10 Main EK, Mc Cain CL, Martini CH. et al. Pregnancy-related mortality in California. Obstet Gynecol 2015; 125: 938-947
• 11 Sancedo M, Deneaux-Tharaux C, Bouvier-Colle MH. French National Experts Committee on Maternal Mortality: Ten years of confidential inquiries into maternal deaths in France 1998-2008. Obstet Gynecol 2013; 122: 752-760
• 12 ACOG Practice Bulletin No. 138. Inherited thrombophilias in pregnancy. Obstet Gynecol 2013; 122: 706–717
• 13 Wik HS, Jacobsen AF, Sandvik I. et al. Prevalence and predictors for post-thrombotic syndrome 3 to 16 years after pregnancy-related venous thrombosis: a population-based, cross-sectional, case-control study. J Thromb Haemost 2012; 10: 840-847
• 14 Sultan AA, Tata LJ, West J. et al. Risk factors for first venous thromboembolism around pregnancy: a population-based cohort study from the United Kingdom. Blood 2013; 121: 3953-3961
• 15 Sultan AA, West J, Stephansson O. et al. Defining venous thromboembolism and measuring its incidence using Swedish health registries: a nationwide pregnancy cohort study. BMJ Open 2015; 5: e008864
• 16 Kline JA, Richardson DM, Than MP. et al. Systematic review and meta-analysis of pregnant patients investigated for suspected pulmonary embolism in the emergency department. Acad Emerg Med 2014; 21: 449-459
• 17 Di Minno MND, Ambrosino P, Ambrosini E. et al. Prevalence of deep vein thrombosis and pulmonary embolism in patients with superficial vein thrombosis: a systematic review and meta-analysis. J Thromb Haemost 2016; 14: 964-972
• 18 Mc Lintock C. Thromboembolism in pregnancy: Challenges and controversies in the prevention of pregnancy-associated venous thromboembolism and management of anticoagulation in women with mechanical prosthetic heart values. Best Pract Res Clin Obstet Gynaecol 2014; 29: 519-536
• 19 Heit JA, Kobbervig CE, James AH. et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005; 143: 697-706
• 20 Pomp ER, Unselig AM, Roosendaal FR. et al. Pregnancy and postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost 2008; 6: 632-637
• 21 Jacobsen AF, Skeldestad FE, Sandset PM. Incidence and risk pattern of venous thromboembolisms in pregnancy and purperium – a register-based case control study. AJOG 2008; 198: 233e1-23e7e
• 22 Kane EV, Calderwood C, Dobbie R. et al. A population-based study of venous thrombosis in pregnancy in Scotland 1980-2005. Eur J Obstet Gynecol Reprod Biol 2013; 169: 223-229
• 23 Larsen TB, Sørensen HT, Gislum M. et al. Maternal smoking, obesity, and risk of venous thromboembolism during pregnancy and the puerperium: a population-based nested case-control study. Thromb Res 2007; 120: 505-509
• 24 Liu S, Rouleau J, Joseph KS. et al. Maternal health study group of the canadian perinatal surveillance system. Epidemiology of pregnancy – associated venous thromboembolism. A population-based study in Canada. J Obstet Gynaecol Can 2009; 31: 611-620
• 25 O’Connor DJ, Scher LA, Gargiulo NJ. et al. Incidence and characteristics of venous thromboembolic disease during pregnancy and the postnatal period: a contempory series. Ann Vasc Surg 2011; 25: 9-14
• 26 Sharma S, Monga D. Venous thromboembolism during pregnancy and the postpartum period: incidence and risk factors in a large Victoria healthy service. Austr NZJ Obstet Gynaecol 2008; 48: 44-49
• 27 Virkus RA, Lokkegaard ECL, Berghoff Th. et al. Venous thromboembolism in pregnancy and puerperal women in Denmark 1995-2005. Thromb Haemost 2011; 106: 304-309
• 28 Parunov LA, Soshitova NP, Ovanesov MV. et al. Epidemiology of venous thromboembolism (VTE) associated with pregnancy. Birth Defects Research 2015; 105: 167-184
• 29 Meng K, Hu X, Peng Y. et al. Incidence of venous thromboembolism during pregnancy and the puerperium: a systematic review and meta-analysis. J Maternal-Fetal Neonatal Med 2014; 28: 245-253
• 30 Marshall AL. Diagnosis, treatment, and prevention of venous thromboembolism in pregnancy. Postgr Med 2014; 126: 25-34
• 31 Kourlaba G, Relakis J, Kontodimas S. et al. A systematic review and meta-analysis of the epidemiology and burden of venous thromboembolism among pregnant women. Int J Gynecol Obstet 2016; 132: 4-10
• 32 Friedman AM, Ananth CV, Prendergast E. et al. Thromboembolism incidence and prophylaxis during vaginal delivery hospitalizations. AJOG 2015; 212: 221e1-e12
• 33 Ghaji N, Boulet SL, Tepper N. et al. Trends in venous thromboembolism among pregnancy-related hospitalizations, United States 1994-2009. AJOG 2013; 209: 433e1-43e8e
• 34 Callaghan WM, Creanga AA, Kuklina EV. Severe maternal morbidity among delivery and postpartum hospitalizations in the United States. Obstet Gynecol 2012; 36: 2-6
• 35 Abbasi N, Balayla J, Laporta DP. et al. Trends, risk factors and mortality among women with venous thromboembolism during labour and delivery: a population-based study of 8 million births. Arch Gynecol Obstet 2014; 289: 275-284
• 36 RCOG Green-top Guideline No. 37a. Reducing the risk of venous thromboembolism during pregnancy and the puerperium. London: RCOG; 2015
• 37 Kevane B, Donnelly J, Di Alton M. et al. Risk factors for pregnancy-associated venous thromboembolism: a review. J Perinat Med 2014; 42: 417-425
• 38 Guimicheva B, Czuprynska J, Arya R. The prevention of pregnancy-related venous thromboembolism. Br J Haematol 2015; 168: 163-174
• 39 Rath W, Tsikouras P, von Tempelhoff G-F. Medikamentöse Thromboembolie-Prophylaxe in Schwangerschaft und Wochenbett: neue Leitlinienempfehlungen und kritischer Leitlinienvergleich. Z Geburtsh Neonatol 2016; 220: 95-105
• 40 AWMF-Leitlinie 003/001 (S3): Prophylaxe der venösen Thromboembolie. 2. Komplett überarbeitete Auflage, 15.10.2015. http://leitlinien. net 1–186
• 41 James AH. Pregnancy and thrombotic risk. Crit Care Med 2010; 38: 557-563
• 42 Brill-Edwards P, Ginsberg JS, Gent M. et al. for the Recurrence of Clot in This Pregnancy (ROCIT) Study Group: Safety of withholding antepartum heparin in women with a previous episode of venous thromboembolism. N Engl J Med 2000; 343: 1439-1444
• 43 Pabinger I, Grafenhofer H, Kaiider A. et al. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Throm Haemost 2005; 3: 949-954
• 44 De Stefano V, Martinelli I, Rossi E. et al. The risk of recurrent venous thromboembolism in pregnancy and purperium without antithrombotic prophylaxis. Br J Haematol 2006; 135: 386-391
• 45 Bates SM, Greer I, Middledorp S. et al. VTE, Thrombophilia, antithrombotic therapy, and pregnancy. Antithrombotic therapy and prevention of thrombosis. 9th ed: American College of Chest Physicians: Evidenced-based Clinical Practice Guidelines. Chest 2012; 141: e691S-e735S
• 46 Chan W-S, Rey E, Kent NE. SOGC Clinical Practice Guideline No. 308. Venous thromboembolism and antithrombotic therapy in pregnancy. JOGC 2014; 36: 527-553
• 47 Pabinger I, Grafenhofer H, Kyrie PA. et al. Temporary increase in the risk for recurrence during pregnanc in women with a history of venous thromboembolism. Blood 2002; 100: 1060-1062
• 48 White RH, Cheng WI, Zhou H. et al. Recurrent venous thromboembolism after pregnancy-associated venous unprovoked thromboembolism. Thromb Haemost 2008; 100: 246-252
• 49 Bramham K, Hunt BJ, Germain S. et al. Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus 2010; 19: 58-64
• 50 Galambosi PJ, Vlander VM, Kaaja RJ. The incidence and risk-factors of recurrent venous thromboembolism during pregnancy. Thromb Res 2014; 134: 240-245
• 51 Barco S, Nijkeuter M, Middledorp S. Pregnancy and venous thromboembolism. Semin Throm Hemost 2013; 39: 549-558
• 52 Gerhardt A, Scharf RE, Greer IA. et al. Hereditary risk factors for thrombophilia and probability of venous thromboembolism during pregnancy and the puerperium. Blood 2016; 128: 2343-2349
• 53 Ziakas PD, Poulou LS, Pavlou M. et al. Thrombophilia and venous thromboembolism in pregnancy: a meta-analysis of genetic risk. Eur J Obstet Gynecol Reprod Biol 2015; 191: 106-111
• 54 Rhéaume M, Durand M, Mahone M. Pregnancy-related venous thromboembolism in asymptomatic women with antithrombin deficiency: a systematic review. Obstet Gynecol 2016; 127: 649-656
• 55 Bezemer ID, van der Meer FIM, Eikenboom JCJ. et al. The value of family history as a risk indication for venous thrombosis. Arch Intern Med 2009; 169: 610-615
• 56 Sorensen HT, Rüs AH, Diaz IJ. et al. Familiar risk of venous thromboembolism: a nationwide cohort study. Thromb Haemost 2011; 9: 320-324
• 57 Sultan AA, West J, Teta LJ. et al. Risk of first venous thromboembolism in pregnant women in hospital: population-based cohort study from England. BMJ 2013; 347: f6099
• 58 James AH. Thrombosis in pregnancy and maternal outcome’s. Birth Defects Research 2015; 105: 159-166
• 59 Jensen TB, Gerds ThA, Gron R. et al. Risk factors for venous thromboembolism in pregnancy. Pharmacoepidemiol and Drug Safety 2013; 22: 1283-1291
• 60 Butwick A, Gutierrez MC, Hilton G. The impact of advanced maternal age on peripartum thromboelastographic coagulation profiles: a prospective observational exploratory study. Can J Anesth 2015; 62: 504-512
• 61 Gizzo S, Noventa M, Anis O. et al. Pharmacological anti-thrombotic prophylaxis after elective caesarean delivery in thrombophilia unscreened women: should maternal age have a role in decision making?. J Perinatal Med 2014; 42: 339-347
• 62 Waldman M, Sheiner E, Sergienko R. et al. Can we identify risk factors during pregnancy for thrombo-embolic events during the puerperium and later in life?. J Matern Fetal Neonatal Med 2016; 28: 1005-1009
• 63 Jacobsen AF, Skjeldestad FE, Sandset PM. Anti- and postnatal risk factors of venous thrombosis: a hospital-based case-control study. J Thromb Haemost 2008; 6: 905-912
• 64 Lindquist P, Dahlback B, Marsal K. Thrombotic risk during pregnancy: a population study. Obstet Gynecol 1999; 94: 595-599
• 65 Sultan AA, West J, Tata LJ. et al. Risk of first venous thromboembolism in and around pregnancy: a population-based cohort study. Br J Haematol 2011; 156: 366-373
• 66 White RH, Keenan CR. Effects of race and ethnicity on the incidence of venous thromboembolism. Thromb Res 2009; 123: S11-s17
• 67 Blondon M, Harrington LB, Righini M. et al. Racial and ethnic differences in the risk of postpartum venous thromboembolism: a population-based, case-control study. J Thromb Haemost 2014; 12: 2002-2009
• 68 Roberts LN, Patel RK, Chitongo P. et al. African-Caribbean ethnicity is associated with a hypercoagulable state as measured by thrombin generation. Blood Coagulation Fibrinolysis 2013; 24: 40-49
• 69 Blondon M, Harrington LB, Boehlen F. et al. Pre-Pregnancy BMI, delivery BMI, gestational weight gain and the risk of postpartum venous thrombosis. Thromb Res 2016; 145: 151-156
• 70 Drife J. Deep venous thrombosis and pulmonary embolism in obese women. Best Pract Res Clin Obstet Gynaecol 2015; 29: 365-376
• 71 Knight M, Kurinczuk JJ, Spark P. et al. Extreme obesity in pregnancy in the United Kingdom. Obstet Gynecol 2010; 115: 989-997
• 72 Beijers HJ, Ferreira I, Spronk HM. et al. Body composition as determinant of thrombin generation is plasma: the Hoorn study. Arteriosklerosis, Thrombosis and Vascular Biology 2010; 30: 2639-2647
• 73 Reaven GM, Scott EM, Grant PJ. et al. Hemostatic abnormalities associated with obesity and the metabolic syndrome. J Thromb Haemost 2005; 3: 1074-1085
• 74 Morgan ES, Wilson E, Melody T et al. An observational study of haemostatic changes, leptin and soluble endoglin during pregnancy in women with different BMIs. Blood Coagul Fibrinolysis 2016 (Epub ahead of print)
• 75 Virkus RA, Lokhegard E, Lidegaard Ø. et al. Risk factors for venous thromboembolism in 1.3 Million pregnancies: a nationwide prospective cohort. PLoS One 2014; 9: e96495
• 76 Sultan A, Grainge MJ, West J. et al. Impact of risk factors on the timing of first postpartum venous thromboembolism: a population-based cohort study from England. Blood 2014; 124: 2872-2880
• 77 Colmorn LB, Ladelund S, Rasmussen S. et al. Risk of venous thromboembolic episode due to caesarean section and BMI: A study in northern Denmark covering 2000-2010. J Obstet Gynaecol 2014; 34: 313-316
• 78 Grandone E, Villani M. Assisted reproductive technologies and thrombosis. Thromb Res 2015; 135 (Suppl. 01) S44-S45
• 79 Rova K, Passmark H, Lindquist PG. Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles. Fertil Steril 2012; 97: 95-100
• 80 Hansen AT, Kesmodel OS, Juul S. et al. Increased venous thrombosis incidence in pregnancies after in vitro fertilization. Hum Reprod 2014; 29: 611-617
• 81 Henrikssen P, Westerland E, Wallen H. et al. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilization: cross sentinel study. BMJ 2013; 346: e8632
• 82 Mor YS, Schenker JG. Ovarian hyperstimulation syndrome and thrombotic events. Am J Reprod Immunol 2014; 72: 541-548
• 83 Tanaka H, Katsuragi S, Osato K. et al. Increase in maternal-death-related venous thromboembolism during pregnancy in Japan (2010–2013). Circ J 2015; 79: 1357-1362
• 84 Robertson L, Wu O, Langhorne P. et al. Thrombosis: Risk and Economic assessment of thrombophilia Screening (TREATS) Study: Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006; 132: 171-196
• 85 Blondon M, Casini A, Hoppe KK. et al. Risks of venous thromboembolism after cesarean section: A meta-analysis. Chest 2016; 150: 572-596
• 86 Tepper NK, Boulet SL, Whiteman MK. et al. Postpartum venous thromboembolism: Incidence and risk factors. Obstet Gynecol 2014; 123: 987-996
• 87 Egan K, Kevane B, Aivile FW. Elevated venous thromboembolism risk in preeclampsia: molecular mechanisms and clinical impact. Biochem Soc Trans 2015; 43: 696-701
• 88 Blondon M, Quon BS, Harrington LB. et al. Association between newborn birth weight and the risk of postpartum maternal venous thromboembolism – a population-based case-control study. Circulation 2015; 131: 1471-1476
• 89 Morris JM, Algert CS, Roberts CL. Incidence and risk factors for pulmonary embolism in the postpartum period. Thromb Haemost 2010; 8: 998-1003
• 90 Danielenko-Dixon DR, Heit JA, Silverstein MD. et al. Risk factors for deep vein thrombosis and pulmonary embolism during pregnancy or postpartum: a population-based, case-control study. AJOG 2001; 184: 104-110
• 91 Bain E, Wilson A, Tooher R et al. Prophylaxis for venous thromboembolism disease in pregnancy and the early postnatal period (Review). Cochrane Database Syst Rev 2014 CD 001659
• 92 Rodger M. Pregnancy and venous thromboembolism `TIPPS`for risk stratification. ASH Education Book 2014; 1: 387-392
• 93 Chauleur C, Gris JC, Laporte S. et al. Use of a Delphi method to facilitate antithrombotic prescription during pregnancy. Thromb Res 2010; 126: 88-92